Cite
Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin
MLA
Li, Rifei, et al. “Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin.” Frontiers in Immunology, vol. 13, Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e99a00763ff2500600fad9d57f993f95&authtype=sso&custid=ns315887.
APA
Li, R., Zhu, X., Zhou, P., Qiao, Y., Li, Y., Xu, Y., & Shi, X. (2022). Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin. Frontiers in Immunology, 13.
Chicago
Li, Rifei, Xinjie Zhu, Peng Zhou, Yuehua Qiao, Yinqian Li, Yice Xu, and Xi Shi. 2022. “Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin.” Frontiers in Immunology 13 (January). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e99a00763ff2500600fad9d57f993f95&authtype=sso&custid=ns315887.